
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INSILICO MEDICINE

InSilico Medicine Cayman TopCo
英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INCLUSION IN FTSE GLOBAL EQUITY INDEX SERIES

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, based on the FTSE Russell's quarterly review results of the FTSE Global Equity Index Series, Insilico Medicine will be included in the FTSE Global Equity Index Series, including the FTSE Global Small Cap Index, the FTSE Global All Cap Index, and the FTSE Global Total Cap Index (the "**Inclusion**"). The Inclusion will take effect on June 22, 2026 (Monday).

The FTSE Global Equity Index Series provides a robust global equity index framework with over 19,000 large-, mid-, small- and micro-cap securities across 49 developed and emerging markets globally.

The Board believes that the Company's inclusion in these three FTSE indexes marks widespread recognition of its solid fundamentals, innovative capabilities, and growth potential. The Inclusion is expected to expand the Company's profile among global institutional investors and analysts, attract capital inflows from funds tracking the indexes to diversify its shareholder base, and support greater trading liquidity for its shares.

The Board appreciates the continued support from the shareholders and investors of the Company.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 8, 2026

As at the date of this announcement, the Board comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.